Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market - GBI Research Reports

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market - GBI Research Reports
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Published Feb 10, 2011
100 pages — Published Feb 10, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market. The report provides in-depth analysis of the major targeted therapeutics. The Market Drivers and Restraints for all the types of Targeted Therapeutics (TT) are analyzed. The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules in the pipeline are mentioned. The regulatory Landscape is analyzed with focus on European and the US scenario. The regulatory landscape details about the major agencies for gene and stem cell therapies. The report profiles all the key companies dealing in TT with main focus on their deals involving M&A and licensing deals.

GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline molecules and key deals will help the companies to make a better future strategy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The report gives insight about the key deals which have taken place between biopharmaceutical companies and their influence. Reasons for considering strategic consolidation as the main objective of the companies have been mentioned. The major types of TT include small molecule drugs, protein/peptide therapeutics, monoclonal antibody therapeutics, RNA interference, gene therapy and stem cell therapy. The market drivers and restraints for these six classes are mentioned. From a commercial perspective there is a huge unmet medical need in difficult to treat diseases like cancer and autoimmune diseases. The unmet need is due to the lack of effective and efficacious therapies based on conventional mode of research. TT has the potential to satisfy this unmet need by being more efficacious, effective and safe. The strategic M&A deals and licensing deals of key companies such as Eli Lilly, Forest Laboratories, Hoffmann La-Roche, Isis Pharmaceuticals, J&J, Pfizer , Biogen, Antisoma and others are analyzed.

Scope

The scope of this report includes -
- Description of major types of TT with key market drivers and restraints.
- Analysis of the leading pipeline therapies which will define the future of TT market.
- Factors driving small molecule drugs, peptide/protein drugs, MAbs, RNA interference therapeutics, gene and stem cell therapy are analyzed.
- Key Regulatory Landscape is detailed for understanding the approval procedure of TT with main focus on gene and stem cell therapy.
- Major companies dealing in TT are profiled and their M&A and Licensing deals are mentioned.
- Key companies studied in this report are Eli Lilly, Pfizer, J&J, Hoffmann La- Roche, Biogen, Isis Pharmaceuticals and Antisoma.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Identify the advantages of TT and understand the potential that it can capture.
- Align your product portfolio to the TT market segment with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading TT segments poised for strong growth.
- Understand the key risks and issues which TT is facing and key solutions in development to address these issues.
- Develop key strategic initiatives by understanding the key focus areas with respect to pipeline portfolio of leading companies.
- Exploit in-licensing and out-licensing opportunities by i

  
Source:
Document ID
GBIHC084MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents33
  List of Tables51
  List of Figures51
Targeted Therapeutics: Introduction61
  GBI Research Guidance61
Targeted Therapeutics: Overview73
  Introduction71
  Targeted Therapy is the Need of the Hour71
    High Side Effects and Toxic Effects of Conventional Therapy71
    Variable Efficacy Rate of Conventional Drugs at the Affected Site71
    Resistance Developed to Conventional Drugs Used to Treat Infections71
  Targeted Therapeutics Market Drivers and Restraints81
    Targeted Therapeutics Market Drivers81
      Difficult Regulatory Pathway is required to be Followed for the Entry of any Generic into the Market81
      Increase in the Number of Patients who are Prescribed Targeted Therapeutics due to Their Higher Efficacy and Specificity81
      Increased Faith Shown by Healthcare Professionals in Targeted Therapeutics is Driving the Market to Newer Heights81
    Targeted Therapeutics Market Restraints91
      Time Lag between Research and Commercialization91
      Regulatory Hindrance to Get Approval for Treatment91
      High Treatment Cost and Low Patient Compliance91
Targeted Therapeutics: Major Types of Targeted Therapeutics1059
  Small Molecules101
    Overview102
  Innovative Small Molecule Therapeutics Market Drivers and Restraints121
    Small Molecule Therapeutics Market Drivers121
      Increased use of Combination Therapies, which Includes Small Molecules with Biologics121
      Increase in R&D for Novel Drug Delivery System, which will Lead to Increase in the Use of Targeted Small Molecule Drugs121
    Innovative Small Molecule Therapeutics Market Restraints121
      Side Effects of Targeted Small Molecule Drugs will be a Market Restraint121
      Drug-Drug Interaction of Small Molecules Leads to Increased Concern over their Use for the Patient Pool who are on Multiple Drugs121
    Profiles of Key Pipeline Molecules131
      Abiraterone Acetate (J&J) Phase I &III131
      BSI-201 with Gemcitabine and Carboplatin (Phase III for Breast Cancer and Lung Cancer; Phase II for Ovarian Cancer) Sanofi-Aventis141
      Aliskiren (Phase III for Congestive Heart Failure, Coronary Disease, Atherosclerosis and Phase II for Diabetic Macular Edema)151
      Velcade is under Clinical Trials for the Indication of Follicular Non-Hodkin s Lymphoma (NHL)161
      Iressa is Undergoing Phase III Trials for Head and Neck Cancer and Phase II Trials for Carcinomas, Malignant Mesothelioma, Breast Cancer, Prostate Cancer, Brain Cancer171
      Nexavar with Tarceva is in Phase III Trial for the Treatment of Hepatocellular Carcinoma181
      Sutent is in Phase III Trial for Renal Cell Carcinoma Adjuvant191
      Telatinib is in Phase II of Development for Gastric Cancer and in Phase I for Colorectal Cancer201
      Enzastaurin is in Phase III of Development for Diffuse Large B-Cell Lymphoma211
      Votrient (pazopanib) with Tykerb (lapatinib) is in Phase III of Development for the Treatment of Inflammatory Breast Cancer221
  Proteins/Peptide Drugs231
    Overview232
  Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints251
    Peptides/Protein Drug Therapeutics Market Drivers251
      Protein or Peptide Drugs have more Potential than Small Molecule Drugs251
      Low Toxicological Side Effects251
    Peptides/Protein Drug Therapeutics Market Restraints251
      Low Compliance by Patients due to Mode of Delivery251
      High Cost of R&D251
    Profiles of Key Pipeline Molecules261
      Pamorelin261
      Epogin261
      AS1411271
      RG 7204282
  Monoclonal Antibodies (MAbs) and Antibody Like Structures301
    Overview302
      Key Trends which will Decide the Future of the MAb Market321
  Monoclonal Antibody Therapeutics, Market Drivers and Restraints331
    Monoclonal Antibody Therapeutics Market Drivers331
      Rapid Uptake of Monoclonal Antibodies has Driven the Monoclonal Antibody Sales Growth331
      Improved Side Effects Profiles and Tolerance of Monoclonal Antibodies Therapy331
      Lack of Effective Conventional Therapies Accelerates Utilization of Monoclonal Antibodies341
      Expanded Indications Open up New Potential Patient Groups341
      Lack of Generics Augmented the Sales Growth of Monoclonal Antibodies341
    Global Monoclonal Antibody Market Restraints351
      High Cost of Monoclonal Antibodies Hampering the Growth of the Treatment Population351
      Adverse Effects Generation of Antibodies against Monoclonal Antibodies in Patients Receiving Monoclonal Antibody Therapy351
      Industry Challenges Majority of MAbs Receive Approval as Last Option Therapies351
    Profiles of Key Pipeline Molecules (MAb)351
      CP-751,871 (figitumumab)351
      MK-0646 (dalotuzumab)361
      SGN-35 (brentuzimab vedotin)361
      Trastuzumab-DM1 (T-DM1)371
      CMC544 (inotuzumab ozogamcin)371
      Arzerra (ofatumumab)371
      Galiximab381
      Benlysta381
      ABT-874391
      Alemtuzumab401
      MEDI-528411
      ABthrax411
      Numax (motavizumab)421
      TB-402421
  RNA Interference431
    Overview431
  RNA Interference Therapeutics Market Drivers and Restraints431
    RNA Interference Therapeutics Market Drivers431
      Dual Mechanism of Action is the Major Factor Driving RNA Therapeutics Market Potential431
      Failure of Conventional Therapies in Curing Chronic Diseases has Created High Unmet Needs441
      Major Breakthrough Technologies in RNA Research and Development Opened up New Markets441
      Increased Funding for RNA Research by Major Countries such as the US and Europe441
    RNA Interference Therapeutics Market Restraints441
      Many RNA Therapies are Failing at Phase III Clinical Development441
      The Characteristics of RNA Structure make them Vulnerable to Human Enzymes451
      Lack of Effective Delivery Technologies that can Deliver RNA Therapies to the Target Site are making RNA Therapies Ineffective451
      RNA Therapies Can Cause Potential Side-Effects and Off-Target Effects451
    Profiles of Key Pipeline Molecules (RNA)451
      Mipomersen451
      LOR-2040461
      Genasense471
      ProSavin481
      Trovax491
      Trabedersen501
      Onconase501
      Alicaforsen512
  Stem Cell Therapies531
    Overview531
  Stem Cell Therapeutics Market Drivers and Restraints541
    Stem Cell Therapeutics Market Drivers541
      Supporting Political Environment on Embryonic Stem Cell Research will Advance the Stem Cell Industry to Prosper in the US541
      Limited Availability of Treatments to Treat Certain Disease Conditions Increases Market Opportunity for Stem Cell Research541
    Stem Cell Therapeutics Market Restraints551
      Stem Cell Research and Development is an Expensive Process which Requires Considerable Funding to Operate551
      Availability of Adequate Reimbursements is Unclear and Leads to a Conundrum551
      Ethical, Legal and Social Issues Persist and Act as a Challenge551
      Identifying, recruiting and retaining the best scientific talents is an intractable process for stem cell research based companies551
    Profile of Key Late Stage Therapies561
      Prochymal561
      Myocell561
      Aldagen ALD-101561
      Ontaril (CX401)561
      StemEx561
      Bone Repair Cells561
      ALD 301571
      Cardiac Repair Cells and Vascular Repair Cells571
      Myoblast Therapy571
      Allogenic Mesenchymal Precursor cells (MPC) and Autologous Mesenchymal Precursor cells571
      Autologous Cellular Therapy CD34 (ACT34-CMI)571
      Allogeneic Adult Mesenchymal Precursor cells571
      Chondrogen571
      PLX-PAD571
      TCA Cellular Therapy Autologous Adult stem cells581
  Gene Therapy581
    Overview581
  Gene Therapy Market Drivers and Restraints581
    Gene Therapy Market Drivers591
      Modification of DNA for the Treatment of Diseases591
      High Prevalence of Complex and Difficult to Treat Diseases591
    Gene Therapy Market Restraints591
      Toxicological Complications due to Improper Insertion of Genes591
      Stringent Regulatory Policies Makes Approval a Complex Process591
      Ethical Issues Involving Germ-line Cells591
    Key Pipeline Candidates601
      AAV-hAADC-2601
      Glybera with Cellcept with Neoral (Phase III)611
      Glybera with CellCept, Neoral and Solumedrol (Phase III)621
      AMT-060 (Phase II)631
      AAV-GAD (Phase II)631
      Cell Based Gene Therapy (Phase II)641
      MSP-36 (Pre-clinical)651
      DWP418 (Phase I)661
      Hemophilia A Gene Therapy (Pre-clinical)661
      Non-Viral Gene Therapy (Phase II)672
Targeted Therapeutics: Regulatory Landscape693
  The US Regulatory Landscape Scenario691
    National Institute for Health (NIH)691
    FDA691
  EU Regulatory Landscape Scenario701
    Committee for Advanced Therapies (CAT)702
Targeted Therapeutics: Competitive Landscape7222
  Antisoma721
    Overview721
    Key Deals721
      Antisoma Acquired Aptamera in January 2005721
      Antisoma Acquires Xanthus Pharmaceuticals in November 2008721
  AVI BioPharma721
    Overview721
    Key Deals731
      AVI BioPharma Enters Into Agreement with Action Duchenne in July 2009731
      AVI BioPharma Acquires Ercole Biotech in March 2008731
      AVI BioPharma Enters Into Licensing Agreement with Eleos in January 2007731
  Biogen731
    Overview731
    Key Deals741
      Biogen Idec Amends its Collaboration with Genentech for GA101 in October 2010741
      Biogen Idec Enters Into Licensing Agreement with Knopp Neurosciences for KNS-760704 in August 2010741
  Cephalon741
    Overview741
    Key Deals751
      Cephalon Enters into Licensing Agreement with Mesoblast in December 2010751
      Cephalon Acquires Mepha Pharma in April 2010751
      Cephalon Acquires Ception Therapeutics in April 2010751
      Cephalon Acquired Arana Therapeutics in August 2009751
      Celator Pharmaceuticals Enters Into Research Agreement with Cephalon in May 2009761
  Eli Lilly761
    Overview761
    Key Deals761
      Adimab Enters Into Licensing Agreement with Eli Lilly in December 2010761
      Eli Lilly Acquires Alnara Pharmaceuticals in July 2010771
      Molecular Templates Enters Into Drug Discovery Collaboration with ImClone Systems in July 2010771
      Eli Lilly Acquires ImClone Systems in November 2008771
      United Therapeutics Enters Into Licensing Agreement with Eli Lilly in November 2008781
  Forest Laboratories781
    Overview781
    Key Deals781
      In December 2010, Gruenenthal Enters Into Licensing Agreement with Forest Laboratories Ireland for GRT 6005781
      TransTech Pharma Enters Into Licensing Agreement with Forest Laboratories791
  Genmab791
    Overview791
    Key Deals791
      Genmab Enters Into Co-Development Agreement with H. Lundbeck in October 2010791
      Genmab Enters Into Research Collaboration with Seattle Genetics in September 2010801
  Gilead Sciences801
    Overview801
    Key Deals801
      Gilead Acquired CGI Pharmaceuticals in July 2010801
      Gilead Sciences Acquired CV Therapeutics in April 2009811
      Gilead Acquired Myogen in November 2006811
  Hoffmann La- Roche (Genentech)821
    Overview821
    Key Deals821
      NovImmune Enters Into Licensing Agreement with Genentech in July 2010821
      A-CUBE Enters Into Collaboration with Chugai Pharmaceutical (Roche) in December 2010821
      Adimab Enters Into Licensing Agreement with Genentech (Roche) in December 2010831
      Horizon Discovery Enters Into Co-Development Agreement with Genentech in April 2009831
      ImmunoGen Enters Into Licensing Agreement with Genentech in December 2008831
  Isis Pharmaceuticals841
    Overview841
    Key Deals841
      Isis Pharmaceuticals Enters Into Collaboration with Xenon Pharmaceuticals in November 2010841
      GlaxoSmithKline Entered Into Licensing Agreement with Isis Pharmaceuticals in March 2010851
      Alnylam Pharmaceuticals Entered Into Licensing Agreement with Isis Pharmaceuticals in April 2009851
      Isis Pharmaceuticals Entered Into Licensing Agreement with Genzyme in June 2008851
      Isis Pharmaceuticals Acquired Symphony GenIsis in September 2007861
      Isis Acquired Orasense and HepaSense from Elan in June 2004861
  Johnson and Johnson (J&J)861
    Overview861
    Key Deals871
      Anchor Therapeutics Enters Into Collaboration and Licensing Agreement With Ortho-McNeil-Janssen in September 2010871
      Oncodesign Enters Into Licensing Agreement with Janssen Pharmaceutica in June 2010871
      Edison Pharmaceuticals Enters Into Licensing Agreement with Centocor in January 2010871
      Xencor Enters Into Licensing Agreement with Centocor in November 2009881
      Johnson &Johnson Acquires Assets and Rights to Alzheimer s Immunotherapy Program from Elan in September 2009891
      Horizon Discovery Signs Licensing Agreement with Ortho Biotech Oncology Research &Development891
      Johnson &Johnson Completes Acquisition of Cougar Biotechnology in July 2009891
  Mesoblast Limited901
    Overview901
    Key Deals901
      Mesoblast Receives Anti-Trust Approval to Acquire Angioblast Systems in 2010901
  Pfizer901
    Overview901
    Key Deals901
      Lpath Enters Into Licensing Agreement with Pfizer in December 2010901
      Ablexis Enters Into Licensing Agreement with Pfizer And Four Other Pharma Companies911
      Pfizer Enters Into Co-Development Agreement with Debiopharm in January 2010911
      Ensemble Discovery Enters Into Co-Development Agreement with Pfizer in January 2010911
      Compugen Enters Into Collaboration Agreement with Pfizer in December 2009911
      Athersys Enters Into Co-Development Agreement with Pfizer in December 2009921
      Adimab Enters Into Co-Development Agreement with Pfizer in December 2009921

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market" Feb 10, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Targeted-Therapeutics-Advancement-in-Gene-Therapy-and-Stem-Cell-Therapy-will-Drive-the-Market-2115-165>
  
APA:
GBI Research Reports. (2011). Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market Feb 10, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Targeted-Therapeutics-Advancement-in-Gene-Therapy-and-Stem-Cell-Therapy-will-Drive-the-Market-2115-165>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.